Holen Sie sich die Stockscreener-App
2.05
11.64%
-0.27
Handel nachbörslich:
2.05
Schlusskurs vom Vortag:
$2.32
Offen:
$2.11
24-Stunden-Volumen:
18,359
Relative Volume:
0.71
Marktkapitalisierung:
$16.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-2.5415
EPS:
-0.8066
Netto-Cashflow:
-
1W Leistung:
-10.87%
1M Leistung:
+10.81%
6M Leistung:
-21.46%
1J Leistung:
-36.14%
1-Tages-Spanne:
$1.99
$2.30
1-Wochen-Bereich:
$1.99
$2.40
52-Wochen-Spanne:
$1.33
$3.78
Neuraxis Inc Stock (NRXS) Company Profile
Firmenname
Neuraxis Inc
Sektor
Branche
Telefon
(812) 689-0791
Adresse
11550 North Meridian Street, Suite 325, Carmel
Vergleichen Sie NRXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
2.05 | 16.60M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuraxis Inc Aktie (NRXS) Neueste Nachrichten
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025 - The Manila Times
NeurAxis to Host First Quarter 2025 Results and Business Update Call on Monday, May 12, 2025 - GlobeNewswire Inc.
The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis - Yahoo Finance
Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems - Yahoo Finance
Small Cap Med-Tech Names Are More Insulated from Tariff Fallout - The Wall Street Transcript
Interview with the CEO: Abivax SA (NASDAQ:ABVX) - The Wall Street Transcript
Onshoring Drug Manufacturing Is Critical, But Not Easy - The Wall Street Transcript
Enphase Energy, Inc. (NASDAQ:ENPH) Given Average Rating of “Hold” by Analysts - Defense World
NeurAxis, Inc. (NASDAQ:NRXS) Stake Reduced by Bank of Montreal Can - Defense World
NeurAxis (NASDAQ:NRXS) Stock Price Up 10.3% – Still a Buy? - Defense World
NRXS stock touches 52-week low at $1.38 amid market challenges By Investing.com - Investing.com South Africa
NRXS stock touches 52-week low at $1.38 amid market challenges - Investing.com India
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS - GlobeNewswire
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on - Bluefield Daily Telegraph
NeurAxis to Present at the Planet MicroCap Showcase: VEGAS in partnership with MicroCapClub on Wednesday, April 23, 2025 & 1x1 Meetings on Thursday, April 24, 2025 - Yahoo Finance
Vagus Nerve Stimulators Market Deep Research Report with - openPR.com
Critical Analysis: CeriBell (NASDAQ:CBLL) versus NeurAxis (NASDAQ:NRXS) - Defense World
Neuraxis stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa
Neuraxis stock hits 52-week low at $1.98 amid market challenges - Investing.com India
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2024 Earnings Call Transcript - MSN
NeurAxis (NASDAQ:NRXS) Trading Down 0.9% – Should You Sell? - Defense World
NeurAxis Stock Gains Post Q4 Earnings And Revenue Growth - Barchart
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth - Zacks Investment Research
NeurAxis (NASDAQ:NRXS) & BioLife Solutions (NASDAQ:BLFS) Head-To-Head Analysis - Defense World
NeurAxis, Inc. Reports Strong Q4 Growth Amid Challenges - TipRanks
NeurAxis revenues increase 43% to USD 761K in Q4 2024 - Medical Buyer
NeurAxis, Inc. Reports Strong Q4 2024 Results - TipRanks
Earnings call transcript: Neuraxis Q4 2024 sees revenue growth, loss narrows - Investing.com Canada
Earnings call transcript: Neuraxis Q4 2024 sees revenue growth, loss narrows By Investing.com - Investing.com South Africa
NeurAxis Better on Q4 Results - Baystreet.ca
NeurAxis, Inc. Reports 43% Revenue Growth in Q4 2024 and Significant Milestones Achieved - Nasdaq
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues - GlobeNewswire
Earnings Scheduled For March 20, 2025 - Benzinga
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025 - The Manila Times
NeurAxis, Inc. Set to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 20, 2025 - Nasdaq
NRXS stock touches 52-week low at $1.99 amid market challenges By Investing.com - Investing.com South Africa
NRXS stock touches 52-week low at $1.99 amid market challenges - Investing.com
Vagus Nerve Stimulators Market Detailed In New Research Report - openPR
NeurAxis (NASDAQ:NRXS) Stock Price Down 2.8% – Here’s Why - Defense World
Chronic Idiopathic Constipation Clinical Trials and Pipeline - openPR
Interview with the Chairman and CEO: The Real Brokerage Inc. (NASDAQ:REAX) - The Wall Street Transcript
Critical Contrast: NeurAxis (NASDAQ:NRXS) & Zynex (NASDAQ:ZYXI) - Defense World
Vagus Nerve Stimulators Market Witness Growth: Booming Demand, - openPR
Analyzing NeurAxis (NASDAQ:NRXS) and Masimo (NASDAQ:MASI) - Defense World
End Of January 2025 Portfolio Review - substack.com
FDA Clears NeurAxis’ Self-Inflating Balloon Device - MPO-mag
Finanzdaten der Neuraxis Inc-Aktie (NRXS)
Es liegen keine Finanzdaten für Neuraxis Inc (NRXS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
Kapitalisierung:
|
Volumen (24h):